article Open AccessTop 1% cited
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Journal of Clinical Oncology · 2019 · Vol. 38(1) · pp. 1–10
Aurélien Marabelle✉(Inserm)Dung T. Le(Sidney Kimmel Comprehensive Cancer Center)Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")Anna Maria Di Giacomo(University of Siena)Ana De Jesus‐Acosta(Sidney Kimmel Comprehensive Cancer Center)Jean-Pierre Delord(Institut Claudius Regaud)Ravit Geva(Tel Aviv Sourasky Medical Center)Maya Gottfried(Meir Medical Center)Nicolas Penel(Centre Oscar Lambret)Aaron R. Hansen(Princess Margaret Cancer Centre)Sarina A. Piha‐Paul(The University of Texas MD Anderson Cancer Center)Toshihiko Doi(National Cancer Center Hospital East)Bo Gao(Blacktown & Mount Druitt Hospital)Hyun Cheol Chung(Yonsei University)José A. López-Martín(Research Institute Hospital 12 de Octubre)Yung-Jue Bang(Seoul National University)Ronnie Shapira Frommer(Sheba Medical Center)Manisha H. Shah(The Ohio State University)Razi Ghori(Merck & Co., Inc., Rahway, NJ, USA (United States))Andrew K. Joe(Merck & Co., Inc., Rahway, NJ, USA (United States))Scott K. Pruitt(Merck & Co., Inc., Rahway, NJ, USA (United States))Luis A. Díaz(Memorial Sloan Kettering Cancer Center)
Abstract
Our study demonstrates the clinical benefit of anti-programmed death-1 therapy with pembrolizumab among patients with previously treated unresectable or metastatic MSI-H/dMMR noncolorectal cancer. Toxicity was consistent with previous experience of pembrolizumab monotherapy.
Genetic factors in colorectal cancerCancer Immunotherapy and BiomarkersCancer Genomics and DiagnosticsPembrolizumabMedicineMicrosatellite instabilityCancerInternal medicineOncologyResponse Evaluation Criteria in Solid TumorsClinical endpointDNA mismatch repairPhases of clinical research
MeSH terms
Antineoplastic Agents, ImmunologicalAdultAgedAged, 80 and overDrug Administration ScheduleFemaleHumansInfusions, IntravenousMaleMiddle AgedNeoplasmsMicrosatellite InstabilityDNA Mismatch RepairYoung AdultProgrammed Cell Death 1 Receptor
Citations
2,871
FWCI
197.26
field-weighted impact
References
26
Percentile
100%
vs. same field & year
Citations per year
Cited by
The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
Frontiers in Immunology · 2020 · 628 citations
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
Annals of Oncology · 2021 · 1,029 citations
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
The Lancet Oncology · 2020 · 2,424 citations
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
Annals of Oncology · 2020 · 1,151 citations
Current treatment and recent progress in gastric cancer
CA A Cancer Journal for Clinicians · 2021 · 1,701 citations
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Annals of Oncology · 2022 · 1,260 citations
References
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
New England Journal of Medicine · 2015 · 9,308 citations
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
Clinical Cancer Research · 2014 · 2,320 citations
Comprehensive molecular characterization of human colon and rectal cancer
Nature · 2012 · 8,551 citations
Microsatellite Instability as a Biomarker for PD-1 Blockade
Clinical Cancer Research · 2016 · 978 citations
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
The Lancet Oncology · 2017 · 2,759 citations
The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
Frontiers in Immunology · 2020 · 628 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.